|Application ||WB, IHC-P, E|
|Other Accession||NP_065891, 154689769|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||122115 Da|
|Application Notes||FNIP2 antibody can be used for detection of FNIP2 by Western blot at 1 - 2 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL.|
|Target/Specificity||FNIP2; Multiple isoforms of FNIP2 are known to exist. This antibody is predicted to not cross-react with FNIP1.|
|Reconstitution & Storage||FNIP2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||FNIP2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||FNIPL, KIAA1450, MAPO1|
|Function||Acts as a co-chaperone of HSP90AA1. Inhibits the ATPase activity of HSP90AA1 leading to reduction in its chaperone activity. Facilitates the binding of client protein FLCN to HSP90AA1 (PubMed:27353360). May play a role in the signal transduction pathway of apoptosis induced by O6-methylguanine- mispaired lesions (By similarity). May be involved in energy and/or nutrient sensing through the AMPK and mTOR signaling pathways (PubMed:18403135). May regulate phosphorylation of RPS6KB1 (PubMed:18663353).|
|Cellular Location||Cytoplasm Note=Colocalizes with FLCN in the cytoplasm|
|Tissue Location||Widely expressed with highest levels in muscle, nasal mucosa, salivary gland, uvula, fat, liver, heart, placenta and pancreas. Moderately expressed in the lung, small intestine, kidney and brain. Lower levels detected in renal cell carcinoma than in normal kidney tissue (PubMed:18403135). Higher levels detected in oncocytoma tumors than in normal kidney. Higher levels detected in renal cell carcinoma tumors than in normal kidney tissue (PubMed:27353360).|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
FNIP2 Antibody: FNIP2 is the second protein found to interact with folliculin, the product of the Birt-Hogg-Dube (BHD) gene. Folliculin is thought to act as a tumor suppressor as mutations or loss of heterozygosity in this gene are associated with BHD syndrome-related renal tumors. Folliculin and FNIP1, a protein that shares 49% identity to FNIP2, bind to AMPK, an important energy sensor in cells that negatively regulates the mammalian target of rapamycin (mTOR), a protein that is thought to be the master switch for cell growth and proliferation. FNIP1 and FNIP2 are able to form homo- and heteromeric multimers, suggesting these proteins may have a functional relationship.
Hasumi H, Baba M, Hong S-B, et al. Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene2008; 415:60-7.
Takagi Y, Kobayashi T, Shiono M, et al. Interaction of folliculin (Birt-Hogg-Dube gene product) with novel Fnip1-like (FnipL/Fnip2) protein. Oncogene2008; 27:5339-47.
Vocke CD, Yang Y, Pavlovich CP, et al. High frequency of somatic frameshift BHD mutations in Birt-Hogg-Dube-associated renal tumors. J. Natl. Cancer Inst.2005; 97:931-5.
Baba M, Hong SB, Sharma M, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc. Natl. Acad. Sci. USA2006; 103:15552-7.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.